Fig. 4

PDO-based drug screening using a kinase inhibitor library. A. Scheme of experiments for the treatment of PDOs with compounds. B. Summary of the responses of PDOs to different compounds used in the screening. Shown are values of percentage of viability versus DMSO. mPO, murine pancreatic organoid. Values below 50 are highlighted in gray. C. In vivo activity of the CHK1 inhibitor (prexasertib) in PDO Sph18–02 grafted subcutaneously in nude mice. Mice were treated with 10 mg/kg prexasertib or vehicle three times per week for two weeks (subcutaneous injection, n = 6). Results are shown as tumor volume (mm³ mean ± s.d.) (Left). *, P < 0.05 (two-tailed unpaired Student’s t test). Body weight change of mice bearing Sph18–02 PDO xenografts after treatment with 10 mg/kg prexasertib or vehicle (Right)